Novartis AG

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial (2025) Pavel ME, Caplin ME, Ruszniewski P, Hertelendi M, Krenning EP, Strosberg JR Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry (2025) Oommen PT, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Journal article, Original article Defining immune reset: achieving sustained remission in autoimmune diseases (2025) Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G, Dörner T, Siegel RM Journal article Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vsTamoxifen in Premenopausal Women with Early Breast Cancer Indirekter Behandlungsvergleich von Ribociclib kombiniert mit nichtsteroidalen Aromatasehemmern und ovarieller Funktionsunterdrückung mit Tamoxifen bei prämenopausalen Frauen mit Brustkrebs im Frühstadium (2025) Lüftner D, Banys-Paluchowski M, Hartkopf AD, Hörner M, Janni W, Langanke D, Müller V, et al. Journal article Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN) (2025) Schmitz-Dräger BJ, Bismarck E, Ebert T, Starlinger R, Dienes K, Ottillinger B, Goebell P, et al. Journal article Evaluating the Accuracy and Reliability of Real-World Digital Mobility Outcomes in Older Adults After Hip Fracture: Cross-Sectional Observational Study (2025) Berge MA, Paraschiv-Ionescu A, Kirk C, Küderle A, Micó-Amigo E, Becker C, Cereatti A, et al. Journal article Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer (2024) Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, et al. Journal article Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device (2024) Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, et al. Journal article